Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1323808rdf:typepubmed:Citationlld:pubmed
pubmed-article:1323808lifeskim:mentionsumls-concept:C0149925lld:lifeskim
pubmed-article:1323808lifeskim:mentionsumls-concept:C0009429lld:lifeskim
pubmed-article:1323808pubmed:dateCreated1992-9-11lld:pubmed
pubmed-article:1323808pubmed:abstractTextSmall cell carcinoma is one of the solid cancers for which chemotherapy is effective and can prolong the survival of patients. There is a general agreement that the standard regimen is PVP (cisplatin/etoposide) or alternating PVP-CAV (cyclophosphamide/doxorubicin/vincristine) therapy, replacing CAV, which had been considered standard. For the improvement of the treatment results of small cell carcinoma combined modality therapy including radiotherapy and/or surgery is essential, especially against limited disease. The effect of prophylactic cranial irradiation is obscure, because of the relapse to other sites of organs and the late complications of brain radiation. The present status of combined modality therapy for small cell carcinoma is reviewed and the future essential trials are discussed.lld:pubmed
pubmed-article:1323808pubmed:languageenglld:pubmed
pubmed-article:1323808pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1323808pubmed:citationSubsetIMlld:pubmed
pubmed-article:1323808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1323808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1323808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1323808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1323808pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1323808pubmed:statusMEDLINElld:pubmed
pubmed-article:1323808pubmed:issn0030-2414lld:pubmed
pubmed-article:1323808pubmed:authorpubmed-author:SaijoNNlld:pubmed
pubmed-article:1323808pubmed:issnTypePrintlld:pubmed
pubmed-article:1323808pubmed:volume49 Suppl 1lld:pubmed
pubmed-article:1323808pubmed:ownerNLMlld:pubmed
pubmed-article:1323808pubmed:authorsCompleteYlld:pubmed
pubmed-article:1323808pubmed:pagination2-9; discussion 10lld:pubmed
pubmed-article:1323808pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:meshHeadingpubmed-meshheading:1323808-...lld:pubmed
pubmed-article:1323808pubmed:year1992lld:pubmed
pubmed-article:1323808pubmed:articleTitleCombined modality therapy for small cell lung cancer.lld:pubmed
pubmed-article:1323808pubmed:affiliationPharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.lld:pubmed
pubmed-article:1323808pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1323808pubmed:publicationTypeReviewlld:pubmed
pubmed-article:1323808pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed